Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kunxian capsule versus leflunomide for IgA nephropathy
ChiCTR1800019606Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Chengdu Medical College
- Start
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of Kunxian Capsule and leflunomide in IgA nephropathy (IgAN) (2 arms), sponsored by The First Affiliated Hospital of Chengdu Medical College. Primary endpoints: 24-hour urinary protein, albumin and 1 more. Planned start Dec 2018; status: not yet recruiting.
02
Drugs
Kunxian Capsuleleflunomide
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on ChiCTR1800019606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800019606.